Survival of multiple myeloma patients tied to levels of ADAR1 enzyme | Study: Multimorbidity rates rise among persons living with HIV | ACC releases guidelines on anticoagulation management after bleeding
December 11, 2017
News for the transfusion medicine and cellular therapy community
Researchers with the University of California at San Diego School of Medicine found that high levels of the ADAR1 enzyme are associated with decreased survival rates among multiple myeloma patients, according to a study in the journal Nature Communications. Regeneration of multiple myeloma cells was reduced in mice without the enzyme.
Choose increased platelet availability When the FDA issues final guidance regarding bacterial risk control strategies for platelets, you will have to decide which approach to use. Our Platelet PGD test is the ONLY way to enable 7-day platelet dating, which ensures a consistent platelet supply, simplifies inventory management and provides inventory flexibility for HLA matched units. Learn More.
The prevalence of multimorbidity among Americans living with HIV and being treated was found to have increased from 8.2% in 2000 to 22.4% in 2009, according to a study of data from 22,969 adult persons living with HIV. The research, published in the journal Clinical Infectious Diseases, evaluated multimorbidity trends among PLWH taking antiretroviral therapy who had age-associated co-existing conditions.
A study supported by the National Heart, Lung, and Blood Institute found that the delivery of powerful clot-busting drugs via catheter for the prevention of post-thrombotic syndrome in patients with deep vein thrombosis was associated with minimal benefit, based on data for almost 700 participants with DVT. The study in The New England Journal of Medicine found similar rates of post-thrombotic syndrome with and without the procedure, but rates of dangerous bleeding were higher with the procedure.
Cell Design Labs was acquired by Gilead Sciences and Kite, Gilead's cell therapy subsidiary, in a deal worth up to $567 million. Cell's new technology platforms will enhance Gilead's research and development efforts in chimeric antigen receptor T-cell and other cellular therapies.
A public offering of more than 4.9 million shares of common stock was priced by Biocept in hopes of raising $3 million. The company intends to use the net proceeds as working capital, as well as to support other general corporate functions.
Fate Therapeutics and the University of California at San Diego entered an agreement to develop chimeric antigen receptor-targeted natural killer cell cancer immunotherapies. Financial details of the deal were not disclosed.
A clinical trial application was filed by CRISPR Therapeutics for its CRISPR gene-edited CTX001, to be developed for the treatment of patients with B-thalassemia. The company plans to initiate a Phase I/II study of the drug in Europe and submit an investigational new drug application to the FDA for sickle cell disease indication, both in 2018.
Topics currently creating a buzz in the AABB HUB include skipping the immediate spin in tube-method antibody screening, transporting blood between hospitals and O-positive cells for male uncrossmatched release. The AABB HUB, the association's online community, provides access to discussions on hot topics in transfusion medicine, regulatory issues, cellular therapies, patient blood management and more. Join the HUB to follow these discussions or submit a comment and post or answer questions in one of the HUB's discussion groups.